Outcome measures at baseline and follow-up points, mean and (SD)
| Outcome | Baseline | Halfway* | 14 weeks |
| PAM | 69.7 (17.8) | 65.8 (14.8) | 68.1 (10.3) |
| FMA-UE† | 37.7 (17.2) | 39.0 (20.1) | 36.4 (22.4) |
| MAL‡ | 2.00 (1.4) | 2.26 (1.5) | 2.94 (1.2) | 3.09 (1.2) | 3.24 (1.3) | 3.17 (1.2) |
| mRS | 2.8 (1.1) | 2.5 (0.8) | 1.9 (0.9) |
| VAS (pain) | 0.8 (1.0) | 2.5 (1.9) | 2.8 (2.3) |
| MoCA§ | 22.6 (6.9) | 24.0 (5.1) | 25.3 (1.0) |
| MoCA¶ | 17.8 (3.4) | 19.0 (1.9) | 18.3 (2.4) |
| AT | 0.2 (0.4) | 0.1 (0.3) | 0.1 (0.3) |
| EQ-5D-5L index | 0.462 (0.3) | 0.585 (0.1) | 0.606 (0.2) |
| EQ-5D-5L VAS | 57.3 (20.7) | 72.7 (9.8) | 74.2 (15.1) |
| SUS | 84.6 (13.1) |
* Performed at week 8 for phase 1 participants; week 7 for phase 2.
†Only performed during phase 1. Participants who started in phase 1 but finished their participation after lock down, did not complete this measure subsequently.
‡How much score | How well score
§Full version applied before lockdown measures (scores out of 30).
¶Telephone version applied after lockdown measures (scores out of 22).
AT, Albert’s Test; EQ-5D-5L, EuroQol-5 Dimensions-5 Level; FMA-UE, FuglMeyer Upper Extremity; MAL, Motor Activity Log; MoCA, Montreal Cognitive Assessment; mRS, Modified Rankin Scale; PAM, Patient Activation Measure; SUS, System Usability Scale; VAS, Visual Analogue Scale (pain).